Healthcare decision-makers are facing significant challenges that will intensify in the coming years as they work to address ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

When the Inflation Reduction Act was signed into law in 2022, it authorized a number of initiatives aimed at reducing the ...

Boehringer Ingelheim won a defense verdict along with GSK in the first Zantac trial but had two subsequent mistrials in Illinois. In 2020, the U.S. Food and Drug Administration announced an ...

Boehringer Ingelheim GmbH is open to more dealmaking to build its obesity portfolio even as it stays “laser-focused” on bringing its first weight-loss drug to market, its global head of therap ...

German drugmaker is vying for a place in the obesity market Company hopes liver data will help it carve out a niche Boehringer Ingelheim GmbH is open to more ... focused” on bringing its first ...

The U.S. FDA Breakthrough Therapy designation is for the treatment of adults with non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) and moderate or advanced fibrosis, based on surv ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the ...